摘要:
The invention relates to compounds of formula (I). These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
The invention relates to compounds of formula (I). These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc',(I) and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc', l and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
The invention relates to compounds of formula (I). These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
Zwiettionic bicyclic compounds of formula (I), wherein, x and w may be the same or different and each independently represents -CH= or -N= and Q represents an aryl or an aromatic heterocyclic group are useful as anti-allergic, anti-inflammatory and/or cytoprotective agents. Pharmaceutical compositions are also disclosed.
摘要:
Disclosed are maleate, tosylate, fumarate, and oxalate salts of the compound 5-(1(S)-Amino-2-Hydroxyethyl)-N-[(2,4-Difluoro- phenyl)-Methyl]-2-[8-Methoxy-2-(Trifluoromethyl)-5-Quinoline]-4- Oxazolecarboxamide, represented by Formula I, and methods of preparing the same.
摘要:
Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar?1 and Ar2¿ are optionally substituted heteroaryl or optionally substituted phenyl; X1 is -O-, -S-, -SO-, -SO¿2?-, -NR?12¿-, -NCOR12- or -NR12SO2R15; (a) is selected from the group consisting of (b), (c), (d) and (e); X2 is -O-, -S- or -NR5-; Y is =O, =S or =NR11; Y1 is H, C¿1?-C6 alkyl, -NR?17R13¿, -SCH¿3, R?19-aryl(CH¿2?)n6-, R?19¿-heteroaryl-(CH¿2?)n6-, -(CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R?15; R1, R2, R3 and R7¿ are H, alkyl, cycloalkyl, -CHF¿2?, -CH2F or -CF3; or R?1 and R2¿, together with the carbon to which they are attached, form an alkylene ring; or R?1 and R2¿ together are =O; R6 is R7 or -OH; and the remaining variables are as defined in the specification, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor.
摘要:
The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc', l and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.
摘要:
The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc',(I) and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.